Bio Roundup: Pelosis Reveal, Alders Deal, Biogens Fails & More
Summary
—In April, Novartis disclosed that a spinal muscular atrophy patient died in a clinical trial of gene therapy Zolgensma, and that the death was “possibly” related to treatment. —Stat reported on the possibility of using CRISPR to edit the DNA of human embryos who would be born as “savior siblings” and donate bone marrow to a living child with a deadly disease. —Late last Friday, an FDA advisory panel voted to recommend approval of an Aimmune Therapeutics (NASDAQ: AIMT) therapy developed to desensitize patients to peanut allergy. —Boundless Bio debuted in San Diego with $46 million to pursue cancer treatments based on mutations found in genetic material not attached to chromosomes. —Amplyx Pharmaceuticals licensed an experimental drug from Novartis for BK viral disease, an infection that can afflict patients who receive kidney or stem cell transplants.
Classifications
AskAI Classifications
LabelsLinked Companies
